PYRIMETHAMINE, A STAT3 INHIBITOR, HAS SYNERGY WITH VENETOCLAX AND IS EFFICACIOUS IN HYPOMETHYLATING AGENT RESISTANT MDS/AML

被引：0
|
作者：
Shastri, A. [1 ]
Zhang, H. [2 ]
Rivera-Pena, B. [2 ]
Chakraborty, S. [2 ]
机构：
[1] Montefiore Med Ctr, Oncol, Bronx, NY USA
[2] Albert Einstein Coll Med, Oncol, Bronx, NY USA
来源：
LEUKEMIA RESEARCH | 2023年 / 128卷
关键词：
D O I：
10.1016/j.leukres.2023.107120
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O07
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pyrimethamine, a STAT3 Inhibitor, Synergizes with Venetoclax and Shows Efficacy in Hypomethylating Agent Resistant MDS and AML
    Rivera, Bianca L.
    Chakraborty, Samarpana
    Shi, Yang
    Zhang, Hui
    Choudhary, Gaurav S.
    Gordon, Shanisha
    Pradhan, Kith
    Fu, Bowen
    Tosic, Isidora
    Zhao, Rongbao
    Goldfinger, Mendel
    Mantzaris, Ioannis
    Carbajal, Milagros
    Ramachandra, Nandini
    Konopleva, Marina
    Frank, David
    Saunthararajah, Yogenthiran
    Verma, Amit
    Shastri, Aditi
    BLOOD, 2022, 140 : 6892 - 6893
  • [2] Pyrimethamine Shows Synergy and Efficacy in Combination With Venetoclax in Preclinical Models of Therapy Resistant MDS/AML
    Rivera-Pena, Bianca
    Chakraborty, Samarpana
    Shi, Yang
    Zhang, Hui
    Zhao, Rongbao
    Choudhary, Gaurav
    Gordon-Mitchell, Shanisha
    Pradhan, Kith
    Fu, Bowen
    Tosic, Isidora
    Schinke, Carolina
    Varshavsky, Asya
    Feld, Jonathan
    Goldfinger, Mendel
    Carbajal, Milagros
    Ramachandra, Nandini
    Konopleva, Marina
    Frank, David
    Saunthararajah, Yogen
    Verma, Amit
    Shastri, Aditi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S355 - S355
  • [3] Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine
    Shastri, Aditi
    Schinke, Carolina
    Yanovsky, Asya Varshavsky
    Bhagat, Tushar D.
    Giricz, Orsolya
    Barreyro, Laura
    Boultwood, Jacqueline
    Pellagati, Andrea
    Yu, Yiting
    Brown, Jennifer R.
    Frank, David A.
    Das, Bhaskar
    Kambhampati, Suman
    Will, Britta
    Steidl, Ulrich
    Verma, Amit
    BLOOD, 2014, 124 (21)
  • [4] THERAPEUTIC TARGETING OF MDS & AML STEM CELLS WITH AN ANTISENSE INHIBITOR OF STAT3
    Shastri, A.
    Teixeira, M.
    Bhattacharya, S.
    Ramachandra, N.
    Lopez, R.
    Ravipati, G.
    Bhagat, T.
    Choudhary, G.
    Bartenstein, M.
    Gordon-Mitchell, S.
    Pradhan, K.
    Pellagatti, A.
    Boultwood, J.
    Kim, Y.
    Woessner, R.
    Will, B.
    Steidl, U.
    Verma, A.
    LEUKEMIA RESEARCH, 2017, 55 : S8 - S8
  • [5] Distinct Role of STAT3 and STAT5 Factors in MDS and AML
    Fasouli, Eirini Sofia
    Giavi, Konstantina
    Makri, Charikleia
    Bystrykh, Leonid
    Bouchla, Anthi
    Athanasiadis, Emmanouil
    Vatsellas, Giannis
    Pappa, Vasiliki
    Katsantoni, Eleni
    BLOOD, 2023, 142
  • [6] Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients
    Rosenbaum, Jan S.
    Kolt, Amal S.
    Hoyt, Scott B.
    Hayes, Gregory M.
    Soldo, Brandi L.
    Thomas, Craig J.
    Starczynowski, Daniel T.
    BLOOD, 2023, 142
  • [7] Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
    Musa Yilmaz
    Hagop Kantarjian
    Nicholas J. Short
    Patrick Reville
    Marina Konopleva
    Tapan Kadia
    Courtney DiNardo
    Gautam Borthakur
    Naveen Pemmaraju
    Abhishek Maiti
    Elias Jabbour
    Nitin Jain
    Ghayas Issa
    Koichi Takahashi
    Koji Sasaki
    Maro Ohanian
    Sherry Pierce
    Guillin Tang
    Sanam Loghavi
    Keyur Patel
    Sa A. Wang
    Guillermo Garcia-Manero
    Michael Andreeff
    Farhad Ravandi
    Naval Daver
    Blood Cancer Journal, 12
  • [8] Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML
    Yilmaz, Musa
    Kantarjian, Hagop
    Short, Nicholas J.
    Reville, Patrick
    Konopleva, Marina
    Kadia, Tapan
    DiNardo, Courtney
    Borthakur, Gautam
    Pemmaraju, Naveen
    Maiti, Abhishek
    Jabbour, Elias
    Jain, Nitin
    Issa, Ghayas
    Takahashi, Koichi
    Sasaki, Koji
    Ohanian, Maro
    Pierce, Sherry
    Tang, Guillin
    Loghavi, Sanam
    Patel, Keyur
    Wang, Sa A.
    Garcia-Manero, Guillermo
    Andreeff, Michael
    Ravandi, Farhad
    Daver, Naval
    BLOOD CANCER JOURNAL, 2022, 12 (05)
  • [9] A Clinical Trial of the STAT3 Inhibitor Pyrimethamine in Chronic Lymphocytic Leukemia
    Brown, Jennifer R.
    Walker, Sarah R.
    Heppler, Lisa N.
    Tyekucheva, Svitlana
    Nelson, Erik
    Klitgaard, Josephine L.
    Nicolais, Maria
    Kroll, Yasmin
    Xiang, Michael
    Yeh, Jennifer E.
    Chaudhury, Mousumi
    Giaccone, Zachary T.
    Fernandes, Stacey
    Supko, Jeffrey G.
    Wu, Catherine J.
    Frank, David A.
    BLOOD, 2018, 132
  • [10] Prolonged Cytopenias After First-Line Treatment With Venetoclax and Hypomethylating Agent in Newly Diagnosed AML/MDS-IB
    Smalinskaite, Tautvile
    Kevlicius, Lukas
    Vaitekenaite, Vilmante
    Daukelaite, Guoda
    Griskevicius, Laimonas
    Zucenka, Andrius
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S332 - S332
12345